SCHEMBL717973

SCHEMBL717973

Cc1c(C(=O)C2CCCCC2)oc2ccc([N+](=O)[O-])cc12

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
NPC1 O15118 8/20 0.46
RAB9A P51151 8/20 0.46
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
CYP2C19 P33261 1/20 0.43
HIF1A Q16665 1/20 0.43
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
CASP6 P55212 1/20 0.41
KMT2A Q03164 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719495 0.81 NPC1 (0.50) ALDH1A1NPC1RAB9ACYP2C19HPGD
SCHEMBL717615 0.80 RAB9A (0.65) ALDH1A1NPC1RAB9ACYP2C19LMNA
SCHEMBL717829 0.80 NPC1 (0.68) ALDH1A1NPC1RAB9ACYP2C19LMNA
SCHEMBL9676565 0.79 MCL1 (0.60) ALDH1A1NPC1RAB9ACA12CA9
SCHEMBL716884 0.79 NPC1 (0.66) ALDH1A1NPC1RAB9ACYP2C19LMNA
SCHEMBL6982862 0.76 HIF1A (0.57) ALDH1A1NPC1RAB9ACA12CA9
SCHEMBL28409651 0.74 HIF1A (0.70) ALDH1A1HIF1AHPGDTSHR
SCHEMBL9486692 0.73 HTT (0.61) ALDH1A1NPC1RAB9ACA12CA9
SCHEMBL24756245 0.73 RAB9A (0.62) ALDH1A1NPC1RAB9ACYP2C19LMNA
SCHEMBL719882 0.73 NPC1 (0.46) ALDH1A1NPC1RAB9ACYP2C19HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885NPC1 902/4885RAB9A 2454/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885NPC1 902/4885RAB9A 2454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.